Navigation Links
Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
Date:11/6/2008

es resulted primarily from increased spending on AZ-004 and AZ-104 as the Company continued development of these product candidates under the Symphony Allegro agreement, increased spending on AZ-003 with continued development of this product candidate under the development agreement with Endo Pharmaceuticals, increased spending for commercial device development and manufacturing process scale-up efforts, increased personnel-related costs to support these efforts, and increased share-based compensation costs.

On January 1, 2006, Alexza adopted FAS 123R and reports employee share-based compensation expense based on the fair value of the award. Share-based compensation was $1,183,000 and $3,821,000 in the quarter and nine month period ended September 30, 2008 compared to $762,000 and $2,038,000 in the comparable periods in 2007. Alexza's Consolidated Statements of Operations include the operations of Symphony Allegro, Inc., its variable interest entity. As the Company has no direct ownership in Allegro, it reduces its net loss by the losses incurred by Allegro. "Loss attributed to noncontrolling interest in Symphony Allegro, Inc." reduced net loss for the quarter and nine month period ended September 30, 2008 by $6.1 million and $15.7 million, and reduced net loss by $3.0 million and $7.7 million in the comparable periods in 2007.

Product Candidates Development Update

-- AZ-004 (Staccato loxapine). Alexza is developing AZ-004 for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. AZ-004 is currently in Phase 3 clinical testing and, if the data from the second Phase 3 trial is positive, the Company projects an NDA filing in early 2010.

In October 2008, the Company completed enrollment in the second of its two Phase 3 clinical trials. Alexza expects to release initial results from this trial by the end of 2008. This trial enrolled 314 bipolar disorder patients with acute agitation at 17 U.S. clinical centers.
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
2. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
3. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
4. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
5. Alexza to Webcast Investor and Analyst Day Presentations
6. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
7. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
8. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
9. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
10. Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... MONDAY, May 20 (HealthDay News) -- Dermatologists are ... sunscreens should help Americans make smarter choices when ... sun protection. The new labels required by ... provide information about whether a sunscreen will protect ... will also have to indicate whether a sunscreen ...
(Date:5/20/2013)... A new Canadian study has uncovered an apparent gender ... than men to get trauma center care following a ... care services in general have been recognized for some ... to the treatment of severe injuries in trauma centers," ... Health Sciences Centre and the University of Toronto, said ...
(Date:5/20/2013)... Rapid Financial Services, LLC (dba RapidAdvance), one ... to small businesses, today announced the debut of its ... 20, the objective of RapidAdvance’s ‘Your Money’s Here’ campaign ... medium and through memorable executions that succinctly convey the ... company. By extension, the advertisements support RapidAdvance’s efforts ...
(Date:5/20/2013)... VHA Inc., the national health ... provider-led population health improvement, announced a new offering ... successfully pursue population health management with a ... accelerate the transition to value-based models of care. ... suite of services, the offering integrates VHA expert ...
(Date:5/20/2013)... 20, 2013 The International Distance Skateboard Association ... location for the best long distance skaters to attend and ... Lucie a venue of raising money for our local Boys ... The IDSA is the authority on long distance races throughout ... our event is safe and organized for all who want ...
Breaking Medicine News(10 mins):Health News:Revised Sunscreen Labels Should Help Consumers Make Wiser Choices 2Health News:Women Less Likely to Get Trauma Center Care After Injury: Study 2Health News:RapidAdvance Turns to National Television Advertising Campaign to Reach Small Business Owners 2Health News:RapidAdvance Turns to National Television Advertising Campaign to Reach Small Business Owners 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4
... China is no cause for alarm , , MONDAY, April ... case of human-to-human transmission of bird flu in China. ... there,s a genetic component to human-to-human transmission of this ... suggests that there,s some genetic component to resistance in ...
... powder-free, ANAHEIM, Calif., April 7, 2008 ... year,s Association of PeriOperative,Registered Nurses (AORN) 55th Congress ... reported being "very concerned" about the surgical,complications related ... facility was powder-free. Powdered gloves have been implicated ...
... The Chehalis,Confederated Tribes will host a special ... Casino May 17 and 18, tribal officials,announced this ... Honor Veterans Benefit," will provide much needed support ... the Freedoms Foundation,s,Return to Honor Program., "We,re ...
... Media, Inc. (AMI),today said that it has made ... to be disclosed on a monthly basis to ... Agreement., The information, which includes the average ... the period April 2007,through March 2008, as well ...
... Pa., April 7, 2008 Genaera,Corporation (Nasdaq: ... Rule 4350(b)(1)(B), that the audit report included in ... fiscal year ended December 31,2007 contained an unqualified ... KPMG LLP, which included a "going concern",explanatory paragraph. ...
... Pa., April 7, 2008 Consumers who,purchased raw ... Bethlehem, Clarion,County, and Clark and Elaine Duncan,s farm ... discard it immediately due to the risk of,Listeria ... Raw milk is milk that has not been ...
Cached Medicine News:Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 2Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 3Health News:Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves 2Health News:Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves 3Health News:Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves 4Health News:Chehalis Tribes Announce Benefit to Help Returning Combat Veterans 2Health News:Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 2Health News:Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 3
(Date:5/20/2013)... May 20, 2013  Echo Pharma Acquisition Limited ("Royalty ... Irish Takeover Rules (the "Announcement"), a firm intention to ... ELN ) to $12.50 per share in cash.  ... not conditional on due diligence.  The $1.00 per share ... reserved the right to waive down the Acceptance Threshold ...
(Date:5/20/2013)... Calif. , May 20, 2013 A ... for use both in space and on Earth was ... The technology assures high quality, secure ... and low-power ultrasound units, like those used in hospitals ... already the diagnostic imaging solution of choice for human ...
(Date:5/20/2013)... , May 20, 2013 Sequent Medical, ... for the SL ("Single Layer") family of WEB ® ... release of these new models in select neurovascular centers ... and superior navigability that will enable physicians to treat ... The SL configurations are made possible by ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Wyle Aided System Gets Named to Space Technology Hall of Fame 2Wyle Aided System Gets Named to Space Technology Hall of Fame 3Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2
Shandon Stackable Slide Storage Cabinet...
The Slide and Paraffin Block Cabinets have versatile drawers which accomodate a variety of slides and paraffin blocks....
Modular Specimen Filing System has five cells that can hold either slides or tissue cassettes....
Shandon Cardboard Slide Folders...
Medicine Products: